Independent, evidence-based peptide science intelligence. Our editorial team combines expertise in peptide chemistry, molecular pharmacology, and biotech industry analysis.
TearSolutions' synthetic peptide Lacripep secured FDA Orphan Drug and Fast Track designations for neurotrophic keratitis, a rare degenerative corneal disease. A Phase 2 trial in 54 patients is now underway.
Parabilis files for Nasdaq IPO after raising $305M privately and securing a Regeneron deal — a milestone for helical peptides that can reach intracellular targets.
Cenna Biosciences wins FDA clearance for a first-in-class peptide that stops amyloid production rather than clearing plaques — a fundamentally different approach to Alzheimer's disease.
GLP-1 prescriptions have more than quadrupled since 2021 and now reach nearly 9,000 per 100,000 U.S. adults. But a 333,000-patient VA study finds that stopping these drugs can erase cardiovascular benefits within months, raising urgent questions about the chronic therapy model.
CordenPharma is acquiring AmbioPharm in a deal that adds peptide API production sites in the US and China, responding to surging GLP-1 manufacturing demand that is reshaping the global CDMO landscape.
Australian peptide biotech Gelteq is entering its first human clinical trial while expanding into veterinary studies, backed by a fresh $3.5 million financing round that signals growing investor appetite for early-stage peptide platforms.
Eli Lilly's triple-agonist peptide retatrutide delivered up to 30.3% average body weight loss in the pivotal TRIUMPH-1 Phase 3 trial — results that put peptide therapeutics on par with bariatric surgery for the first time.
Kither Biotech's inhaled peptide KIT2014 just cleared Phase 1 testing. The drug targets COPD through a novel cAMP signaling mechanism — and it could change how we think about delivering peptides to the lungs.
The FDA will hold an advisory committee meeting in July 2026 to review 7 peptides for compounding pharmacy use, while removing 12 from the restrictive Category 2 bulks list. The move follows direct pressure from Health Secretary RFK Jr. and the MAHA movement, marking the most significant peptide regulatory shift in a decade.
Vedana Therapeutics emerges from stealth with $46M Series A to develop anti-PACAP antibody therapies for migraine prevention. Led by the veterans who built the CGRP drug class, the startup targets a neuropeptide pathway that could help the 50%+ of patients who don't respond to current treatments.
A new meta-analysis of 36 randomized controlled trials reveals GLP-1 receptor agonists cause 1.5 kg of lean body mass loss — 28% of total weight reduction. The findings raise urgent questions about body composition monitoring in the era of widespread GLP-1 prescribing.
Sciwind Biosciences' cAMP-biased GLP-1 analogue ecnoglutide shows no clinically significant drug-drug interactions with rosuvastatin or digoxin in a Phase 1 study, while delivering 11.2% weight loss over 14 weeks. The findings support the peptide's march toward regulatory filing after two positive Phase 3 trials published in The Lancet.
